
Paul G Kluetz MD
Genitourinary Oncology, Hematologic Oncology
Deputy Director, Oncology Center of Excellence, U.S. FDA Assistant Professor, Georgetown University
Join to View Full Profile
3800 Reservoir Rd NwDiv Of Hospital Medicine Gorman 3Washington, DC 20007
Phone+1 202-444-3976
Dr. Kluetz is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- Dr. Paul Kluetz is an oncologist in Washington, DC. He received his medical degree from University of Pittsburgh School of Medicine and has been in practice 14 years. He specializes in genitourinary oncology.
Education & Training
- National Institutes of Health Clinical CenterFellowship, Hematology and Medical Oncology, 2008 - 2010
- University of MarylandResidency, Internal Medicine, 2005 - 2007
- University of MarylandResidency, Emergency Medicine, 2003 - 2005
- University of Pittsburgh School of MedicineClass of 2003
- University of Colorado at Boulder BS, Computer Information Systems, 1989 - 1993
- University of Colorado at Boulder BS, Computer Information Systems, 1989 - 1993
Certifications & Licensure
- DC State Medical License 2011 - 2027
- MD State Medical License 2007 - 2014
- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Medical Oncology
Publications & Presentations
PubMed
- 1 citationsUsing patient-reported outcomes and health-related quality of life data in regulatory decisions on cancer treatment: highlights from an EMA-EORTC workshop.Madeline Pe, Caroline Voltz-Girolt, Jill Bell, Vishal Bhatnagar, Jan Bogaerts
The Lancet. Oncology. 2025-04-14 - Use of patient-reported outcomes to inform symptom and functional outcomes in cancer drug regulatory decisions: challenges and future directions.Francesco Pignatti, Peter Mol, Chantal Quinten, Douwe Postmus, Anja Schiel
The Lancet. Oncology. 2025-04-14 - FDA approvals in 2024: new options for patients across cancer types and therapeutic classes.Sundeep Agrawal, Esther Park, Paul G Kluetz
Nature Reviews. Clinical Oncology. 2025-04-11
Journal Articles
- Analysis of Time to Treatment Discontinuation of Targeted Therapy, Immunotherapy, and Chemotherapy in Clinical Trials of Patients with Non-Small Cell Lung CancerG R Oxnard, G M Blumenthal, P G Kluetz, R Pazdur, Annals of Oncology
Abstracts/Posters
- 2017-2018 Hematology Drug Approvals at the Food and Drug Administration (FDA): Communication of Patient-Reported Outcomes (PRO) Information in FDA Clinical Reviews and...Paul Kluetz, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
- Botanical Product Use Among Multiple Myeloma Patients in Commercial Drug TrialsPaul Kluetz, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Authored Content
- Lancet Oncology Audio Blog- Patient Reported OutcomesMay 2018
Press Mentions
- Broadening Clinical Trial Eligibility: A Tricky Balancing ActAugust 16th, 2024
- The Lonely Quest to Create a Commission to Investigate Covid-19June 22nd, 2021
- FDA Pilot Program to Communicate Patient Reported Outcomes from Cancer Clinical TrialsJune 26th, 2020
- Join now to see all
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: